Logo Logo Logo Logo Logo
  • COMPANY
    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE
    • OPTIREACH Technology
    • Antibody Fragment Technology
    • Neuroprotective approach for eye diseases
    • Publications
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 Acute Optic Neuritis
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources
  • COMPANY

    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE

    • OPTIREACH Technology
    • Antibody Fragment Technology
    • Neuroprotective approach for eye diseases
    • Publications
  • PIPELINE

    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 Acute Optic Neuritis
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources
Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum

...

31 January, 2023
Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME)
05 January, 2023
Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent Licaminlimab (OCS-02) in acute anterior uveitis.
22 November, 2022
Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development
03 November, 2022
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology
17 October, 2022
Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema
06 September, 2022
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease
23 August, 2022
First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 for Inflammation and Pain following Cataract Surgery
29 June, 2022
Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma
02 March, 2022
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer
08 February, 2022
Show more
Contact us

Oculis Holding AG

Bahnofstrasse 7
6300 Zug
Switzerland

+41 58 810 0182

 

info@oculis.com

Copyright © 2023 Oculis

 

Oculis SA

EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne – Switzerland

+41 21 711 3970

    © Oculis – Privacy Policy – Terms of Use  – Cookie Policy    

    © L’autreagence 2019 – 2023